Clinical trial NCT02009579: ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Official title: BGOG-cx1/ENGOT-cx1: "Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Uterine Cervical Neoplasms
Keywords: Uterine Cervical Cancer
Paclitaxel
Carboplatin
Nintedanib
Lead sponsor: Belgian Gynaecological Oncology Group
Sponsor class: OTHER
Collaborators: name: Grupo Español de Investigación en Cáncer de Ovario
name: Mario Negri Gynecologic Oncology group (MaNGO)
name: Multicenter Italian Trials in Ovarian Cancer (MITO)
name: North Eastern German Society of Gynaecological Oncology
First posted: 2013-12-12
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Indication:

Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior radiochemotherapy or neo-adjuvant chemotherapy is allowed.

Study design:

This is a phase II randomized, double blind and placebo controlled trial evaluating the efficacy of Nintedanib/placebo in combination with the standard carboplatin and paclitaxel followed by Nintedanib/placebo maintenance in the treatment of patients with advanced or recurrent cervical cancer.

A total of 120 patients will be randomized between the experimental and control arm in a 1:1 ratio. Randomization will be stratified for 1previous chemotherapy for metastatic disease (yes/no) and 2disease status (Stage IVB primary versus recurrent disease).

Experimental arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.

Control arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.

Subjects without evidence of disease progression after completion or discontinuation of the study treatment will be followed until radiographic disease progression, withdrawal of consent or death.


Eligibility criteria: Inclusion Criteria:

* Female subjects more than 18 years of age
* Histologically or cytologically confirmed advanced (\[FIGO\] stage IVB), or recurrent/persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix will be eligible.
* Prior treatment with angiogenesis inhibitors is allowed
* Up to one prior line of chemotherapy for metastatic cervical cancer is allowed.

  * Treatment of primary disease with concomitant cisplatinum chemotherapy during radiotherapy is allowed and does not count as a line of chemotherapy for metastatic disease.
  * Treatment of primary disease with neoadjuvant chemotherapy before radical local surgery is allowed and does not count as a line of chemotherapy for metastatic disease.
  * Treatment of primary disease with neoadjuvant chemotherapy before radical local surgery followed by adjuvant radiochemotherapy is allowed and does not count as a line of chemotherapy for metastatic disease.
  * Treatment of primary disease with neoadjuvant chemotherapy before radical local surgery followed by adjuvant radiotherapy is allowed and does not count as a line of chemotherapy for metastatic disease.
* Life expectancy at least 3 months.
* ECOG Performance status score of 0 or 1
* At least one measurable lesion according to RECIST 1.1 criteria
* Signed and dated written informed consent prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation

Exclusion Criteria:

* Known hypersensitivity to the trial drugs or to their excipients (including peanut or soya).
* Brain or leptomeningeal metastases.
* Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels.
* Tumor infiltrating the mucosa of the bowel or bladder, or known fistulas between the tumor and the gastrointestinal or urinary tract.
* Radiographic evidence of cavitary or necrotic tumours
* Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial.
* Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid \<325 mg per day).
* Major injuries within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
* History of clinically significant haemorrhagic or thromboembolic event in the past 6 months.
* Known inherited predisposition to bleeding or thrombosis.
* Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina within the past 6 months, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure \> NYHA II, serious cardiac arrhythmia, pericardial effusion).
* History of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months.
* Abnormal renal, liver or bone marrow function defined as:

  * Proteinuria CTCAE grade 2 or greater
  * Creatinin \> 2 ULN or GFR \< 30 ml/min
  * Hepatic function: total bilirubin outside of normal limits; ALT or AST \> 1.5 ULN in pts without liver metastasis. For Pts with liver metastases: total bilirubin outside of normal limits, ALT or AST \> 2.5 ULN
  * Coagulation parameters: International normalised ratio (INR) \> 2, prothrombin time (PT) and partial thromboplastin time (PTT) \> 50% of deviation of institutional ULN
  * Absolute neutrophil count ( ANC) \< 1500/µl, platelets \< 100000/µl, haemoglobin \< 9.0 g/dl
* Other malignancies within the past 3 years or other malignancy with recurrence in the past 3 years or with high risk of recurrence in the first year. In exception to this rule, the following malignancies may be included: non-melanomatous skin cancer (if adequately treated) , any premalignant (e.g. in situ) carcinoma, or basocellular carcinoma.
* Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy.
* Active or chronic hepatitis C and/or B infection or known HIV infection (based on medical file, only for Italy a mandatory screening test for HIV should be performed for all patients who did not have this test within the last 3 months before the study treatment start).
* Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.
* Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
* Patients of child-bearing potential who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner or sexual abstinence for participating females) during the trial and for at least three months after end of active therapy.
* Pregnancy or breast feeding, female patients must have a negative pregnancy test (β-HCG test in urine or serum) prior to commencing study treatment, if applicable.
* Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
* Active alcohol or drug abuse.

Primary outcomes:
measure: Progression free survival
timeFrame: 1.5 years after LPI
Secondary outcomes:
measure: Safety and toxicity
timeFrame: 5 years after LPI
measure: Overall survival
timeFrame: 5 years after LPI
measure: Patient health status
timeFrame: 5 years after LPI
measure: Overall survival
timeFrame: 5 years after LPI
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: CHU Saint-Pierre
city: Bruxelles
country: Belgium
facility: Institut Jules Bordet
city: Charleroi
country: Belgium
facility: Grand Hopital de Charleroi
city: Edegem
country: Belgium
facility: UZ Antwerpen
city: Kortrijk
country: Belgium
facility: AZ Groeninge
city: Leuven
country: Belgium
facility: UZ Leuven
city: Liege
country: Belgium
facility: CHR Citadelle
city: Liège
country: Belgium
facility: CHU de Liège
city: Namur
country: Belgium
facility: Clinique et maternite St. Elisabeth
city: Yvoir
country: Belgium
facility: Cliniques Universitaires mont godinne
city: Berlin
country: Germany
facility: Charité Med Uni Berlin
city: Dresden
country: Germany
facility: Universitätsklinikum Carl Gustav Carus Dresden
city: Essen
country: Germany
facility: Kliniken Essen Mitte
city: Gottingen
country: Germany
facility: Georg-August University Göttingen
city: Greifswald
country: Germany
facility: Medical University Greifswald
city: Tubingen
country: Germany
facility: University Tübingen
city: Aviano
country: Italy
facility: Centro Riferimento Oncologico
city: Brescia
country: Italy
facility: Spedali Civili
city: Catania
country: Italy
facility: Azienda Ospedaliera Cannizzaro
city: Milano
country: Italy
facility: National Cancer Institute
city: Naples
country: Italy
facility: Istituto Nazionale Tumori-Pascale Naples
city: Padova
country: Italy
facility: Padova Istituti Oncologico Veneto
city: Pisa
country: Italy
facility: University Pisa
city: Reggio Emilia
country: Italy
facility: AUSL Reggio Emilia
city: Rome
country: Italy
facility: Poloclinico A Gemelli
city: Torino
country: Italy
facility: Mauriziano -Torino
city: Torino
country: Italy
facility: S. Anna Torino
city: Córdoba
country: Spain
facility: Hospital Provincial Reina Sofia
city: Madrid
country: Spain
facility: H. Ramón y Cajal
city: Madrid
country: Spain
facility: Hospital Clinico San Carlos
city: Murcia
country: Spain
facility: Hospital Universitario Morales Meseguer
city: Palma Mallorca
country: Spain
facility: Hospital Son Llatzer
Study officials:
References: